Metabolic Health
GLP-1 receptor agonists and dual/triple incretin receptor agonists studied for metabolic regulation, appetite signalling, and body composition research — including next-generation compounds such as Retatrutide, Tirzepatide, and Semaglutide analogues.
Jastreboff, A.M. et al. (2023) demonstrated that Retatrutide (GGG tri-agonist) produced up to 24.2% body weight reduction over 48 weeks in phase 2 trials — N Engl J Med, 389, 514-526. [View Publication]
HGH Fragment 176-191
Strength
Lipolytic HGH fragment studied for fat metabolism without IGF-1 elevation.
For research purposes only
Availability: Out of Stock
AOD9604
Strength
hGH fragment studied for fat metabolism without insulin resistance.
For research purposes only
Availability: In Stock
The UltiFstack
Strength
Advanced tri-peptide blend targeting fat metabolism, GH axis stimulation, and mitochondrial energy regulation.
For research purposes only
Availability: Out of Stock
Tesamorelin
Strength
GHRH analogue investigated for visceral fat reduction and GH axis research.
For research purposes only
Availability: In Stock
Retatrutide
Strength
Triple receptor agonist with the highest weight reduction reported in phase 2 trials.
For research purposes only
Availability: In Stock
Tirzepatide
Strength
Dual GIP/GLP-1 agonist showing superior weight reduction in clinical models.
For research purposes only
Availability: Out of Stock
Semaglutide
Strength
GLP-1 receptor agonist studied for metabolic regulation and appetite control.
For research purposes only
Availability: Out of Stock
Mots-C
Strength
Mitochondria-derived peptide for metabolic and longevity research.
For research purposes only
Availability: In Stock